Apellis Pharmaceuticals Inc (APLS)
33.00
-1.63
(-4.71%)
USD |
NASDAQ |
Jan 08, 16:00
32.88
-0.12
(-0.36%)
After-Hours: 20:00
Apellis Pharmaceuticals SG&A Expense (Quarterly): 121.98M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Biogen Inc | 588.40M |
| Biomarin Pharmaceutical Inc | 253.50M |
| Ionis Pharmaceuticals Inc | 61.60M |
| QuidelOrtho Corp | 186.40M |
| Moderna Inc | 281.00M |